<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921386</url>
  </required_header>
  <id_info>
    <org_study_id>CLAR-16015</org_study_id>
    <nct_id>NCT02921386</nct_id>
  </id_info>
  <brief_title>The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate</brief_title>
  <official_title>A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clarus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label, randomized, cross-over, pharmacokinetic study designed to determine
      the effect of meals of various amounts of fat given immediately prior to dosing on the
      pharmacokinetics of oral testosterone undecanoate. Approximately 20 hypogonadal subjects will
      be dosed for a 14 day run-in period. This will be followed by a randomized sequence of five
      periods over a 6 day confinement period. Subjects will receive a randomly ordered sequence of
      breakfast meals containing various amounts of fat, fasting, 15 g, 30 g, 45 g and a high fat
      breakfast consistent Guidance for Industry on Food-Effect Bioavailability and Fed
      Bioequivalence Studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, randomized, cross over, pharmacokinetic study. Subjects will
      initially be dosed for 2 weeks (Run-In Phase) to allow suppression of endogenous testosterone
      production, while allowing the oral TU to reach steady state. The subjects will then be
      confined to a clinical unit in which they undergo the PK Phase of the study. During the PK
      Phase of the study, subjects will undergo a five-period cross-over in which oral TU is dosed
      twice daily. Subjects will dose in the morning and in the evening immediately prior to
      protocol-defined meals. The protocol-defined breakfasts will contain various levels of fat
      including 15 g, 30 g, 45 g, a breakfast consistent with the fat and calorie content of the
      high-fat breakfast consistent with recommendations in the Guidance for Industry on
      Food-Effect Bioavailability and Fed Bioequivalence Studies (December 2002), or while fasting
      (with no meal until 4 hours post-dose). Subjects will be randomized to a designated sequence
      of the protocol-defined breakfasts, or the fasted state. The subjects will be required to
      consume the entire breakfast within 20 minutes during the PK Phase. The protocol-defined
      evening meal will be required to be consumed within 20 minutes. The 5 meal periods will occur
      on sequential days.

      Approximately twenty (20) subjects will be enrolled in order to ensure completion of 16
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">January 21, 2017</completion_date>
  <primary_completion_date type="Actual">January 21, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open-label, randomized, 5-period crossover food effect study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax-am for Oral TU Across Breakfast With Varying Fat Content</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
    <description>Peak Concentration after morning dose (Cmax) for oral testosterone undecanoate taken after a fasting breakfast of varying fat content.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Peak Concentration (Tmax-am)</measure>
    <time_frame>12 hours</time_frame>
    <description>The time of peak concentration (Tmax-am) will be assessed within each relevant dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC-am)</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
    <description>The 12 hours following morning dose area under the curve (AUC) will assessed for each sequence of breakfasts with varying fat content.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Weighted Average Total Testosterone Concentration (Cavg-am)</measure>
    <time_frame>12 hours</time_frame>
    <description>The time weighted average of total testosterone concentration will be assessed for each dosing interval.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Breakfast A - Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breakfast B - 15 g fat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breakfast C - 30 g fat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breakfast D - 45 g fat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breakfast E - High Fat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Testosterone Undecanoate</intervention_name>
    <description>All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
    <arm_group_label>Breakfast A - Fasting</arm_group_label>
    <arm_group_label>Breakfast B - 15 g fat</arm_group_label>
    <arm_group_label>Breakfast C - 30 g fat</arm_group_label>
    <arm_group_label>Breakfast D - 45 g fat</arm_group_label>
    <arm_group_label>Breakfast E - High Fat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man 18 to 65 years of age, inclusive, with a clinical diagnosis of hypogonadism
             (signs/symptoms consistent with hypogonadism for testosterone naïve subjects and
             history of signs/symptoms for subjects who have received prior treatment) as well as
             testosterone levels consistent with hypogonadism as defined by 2 morning total T
             values of &lt;300 ng/dL (between 6:00 and 10:00 AM drawn on 2 separate days
             [approximately 7 (±2) days apart].

          2. Adequate venous access in the left or right arm to allow collection of a number of
             blood samples via a venous cannula.

          3. Must be naïve to androgen-replacement therapy or washed out of prior androgen
             replacement therapies; that is, be willing to cease current T treatment or currently
             not be taking T treatment, (washout durations specified in exclusion criterion #1).
             Subjects must remain off all forms of T, except for dispensed study drug, throughout
             the entire study.

          4. Subjects on replacement therapy for hypopituitarism or multiple endocrine deficiencies
             must be on stable doses of thyroid hormone and adrenal replacement hormones for at
             least 14 days before Screen 1.

          5. Has voluntarily given written informed consent to participate in this study.

        Exclusion Criteria:

          1. Received oral topical (eg, gel or patch), intranasal, or buccal T therapy within the
             previous 2 weeks, intramuscular T injection of short-acting duration (eg, T enanthate,
             T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting
             duration (eg, AVEED) within the previous 20 weeks, or T implantable pellets
             (Testopel®) within the previous 6 months.

          2. Has an intercurrent disease deemed clinically significant in the opinion of the
             investigator of any type; in particular, liver, kidney, uncontrolled or poorly
             controlled heart disease, including hypertension, congestive heart failure or coronary
             heart disease, or psychiatric-illness, including severe depression.

          3. Has had a recent (within 2 years) history of stroke, transient ischemic attack, or
             acute coronary event.

          4. Has a mean of the triplicate assessment of sBP &gt; 150 mm Hg and/or dBP &gt; 90 mm Hg at
             screening (if prescribed antihypertensives, subject should be taking medications on
             the day of the screening visit with a sip of water). Subjects &lt; 60 years of age and
             prescribed antihypertensives will be excluded if the mean of the triplicate assessment
             of sBP &gt; 140 mm Hg and/or dBP &gt; 90 mm Hg at screening.

          5. Has had recent (within 2 years) history of angina or stent (coronary or carotid)
             placement.

          6. Has untreated, severe obstructive sleep apnea.

          7. Has clinically significant abnormal laboratory values, including serum transaminases &gt;
             2 × upper limits of normal (ULN), serum bilirubin &gt; 1.5 × ULN and serum creatinine &gt;
             1.5 × ULN.

          8. Has a hematocrit (HCT) value of &lt; 35% or &gt; 48%.

          9. Has a history of polycythemia, either idiopathic or associated with TRT treatment.

         10. Is a diabetic subject with a glycosylated hemoglobin &gt; 8.5%.

         11. Has a body mass index (BMI) ≥ 38 kg/m2.

         12. Has been on stable doses of antihypertensive medication for &lt; 3 months.

         13. Has an abnormal prostate digital rectal examination [(DRE); palpable nodules],
             elevated PSA (serum PSA &gt; 4.0 ng/mL), I-PSS &gt; 19 points at screening, and/or history
             of, or current or suspected, prostate cancer.

         14. Has a history of, or current or suspected, breast cancer.

         15. Has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to
             venipuncture or intravenous cannulation within the previous 2 years.

         16. Use of dietary supplements such as saw palmetto or phytoestrogens and any dietary
             supplements that may increase total T, such as androstenedione or
             dehydroepiandrosterone within the previous 4 weeks.

         17. Has known malabsorption syndrome and/or current treatment with oral lipase inhibitors
             (eg, orlistat [Xenical®]) and/or bile acid-binding resins (eg, cholestyramine
             [Questran®], colestipol [Colestid®]) or treatments that promote gastric emptying (eg,
             metoclopramide [Reglan®]).

         18. Inability to observe all rules and smoking restrictions in place at the clinical
             facility during confinement.

         19. Has history of abuse of alcohol or any drug substance within the previous 2 years.

         20. Poor compliance or unlikely to keep clinic appointments and remain for entire
             confinement period.

         21. Has received any drug as part of another research study within 30 days of initial dose
             administration in this study.

         22. Donated blood (≥ 500 mL) within the 12-week period before the initial study dose.

         23. Current use of the following groups of drugs that effect T levels, T metabolism or
             levels of T metabolites, namely antiandrogens, 5-alpha-reductase inhibitors (eg,
             dutasteride, finasteride), estrogens, long-acting opioid analgesics (eg, methadone
             hydrochloride, buprenorphine hydrochloride) or human growth hormone (HGH).

         24. Unwilling or unable to follow the dietary requirements for this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Swerdloff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809-3017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <results_first_submitted>March 5, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2018</results_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Testosterone Undecanoate 237 mg BID</title>
          <description>Subjects complete Sequence A-E. Amount of Fat Varies by Sequence. Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to breakfast and immediately prior to dinner.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Sequence A: Fasting</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sequence B: 15 g Fat Breakfast</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sequence C: 30 g Fat Breakfast</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sequence D: 45 g Fat Breakfast</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sequence E: FDA High Fat Breakfast</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Testosterone Undecanoate</title>
          <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum testosterone at screening (ng/dL)</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109.7" spread="85.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax-am for Oral TU Across Breakfast With Varying Fat Content</title>
        <description>Peak Concentration after morning dose (Cmax) for oral testosterone undecanoate taken after a fasting breakfast of varying fat content.</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Breakfast A - Fasting</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O2">
            <title>Breakfast B - 15 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O3">
            <title>Breakfast C - 30 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O4">
            <title>Breakfast D - 45 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O5">
            <title>Breakfast E - High Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax-am for Oral TU Across Breakfast With Varying Fat Content</title>
          <description>Peak Concentration after morning dose (Cmax) for oral testosterone undecanoate taken after a fasting breakfast of varying fat content.</description>
          <units>ng/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.7" spread="48.6"/>
                    <measurement group_id="O2" value="334.7" spread="57.7"/>
                    <measurement group_id="O3" value="529.7" spread="33.9"/>
                    <measurement group_id="O4" value="506.0" spread="37.8"/>
                    <measurement group_id="O5" value="463.4" spread="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Peak Concentration (Tmax-am)</title>
        <description>The time of peak concentration (Tmax-am) will be assessed within each relevant dosing interval.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Breakfast A - Fasting</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O2">
            <title>Breakfast B - 15 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O3">
            <title>Breakfast C - 30 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O4">
            <title>Breakfast D - 45 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O5">
            <title>Breakfast E - High Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax-am)</title>
          <description>The time of peak concentration (Tmax-am) will be assessed within each relevant dosing interval.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="0.00" upper_limit="4.17"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.00" upper_limit="11.92"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.83" upper_limit="6.00"/>
                    <measurement group_id="O4" value="2.000" lower_limit="1.92" upper_limit="11.92"/>
                    <measurement group_id="O5" value="2.000" lower_limit="0.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC-am)</title>
        <description>The 12 hours following morning dose area under the curve (AUC) will assessed for each sequence of breakfasts with varying fat content.</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Breakfast A - Fasting</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O2">
            <title>Breakfast B - 15 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O3">
            <title>Breakfast C - 30 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O4">
            <title>Breakfast D - 45 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O5">
            <title>Breakfast E - High Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC-am)</title>
          <description>The 12 hours following morning dose area under the curve (AUC) will assessed for each sequence of breakfasts with varying fat content.</description>
          <units>ng*hr/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1905" spread="45.2"/>
                    <measurement group_id="O2" value="2428" spread="51.3"/>
                    <measurement group_id="O3" value="3279" spread="33.6"/>
                    <measurement group_id="O4" value="3395" spread="34.7"/>
                    <measurement group_id="O5" value="3187" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Weighted Average Total Testosterone Concentration (Cavg-am)</title>
        <description>The time weighted average of total testosterone concentration will be assessed for each dosing interval.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Breakfast A - Fasting</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O2">
            <title>Breakfast B - 15 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O3">
            <title>Breakfast C - 30 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O4">
            <title>Breakfast D - 45 g Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
          <group group_id="O5">
            <title>Breakfast E - High Fat</title>
            <description>Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
Oral Testosterone Undecanoate: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods</description>
          </group>
        </group_list>
        <measure>
          <title>Time Weighted Average Total Testosterone Concentration (Cavg-am)</title>
          <description>The time weighted average of total testosterone concentration will be assessed for each dosing interval.</description>
          <units>ng/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.0" spread="45.4"/>
                    <measurement group_id="O2" value="203.7" spread="51.3"/>
                    <measurement group_id="O3" value="275.1" spread="33.6"/>
                    <measurement group_id="O4" value="285.1" spread="34.7"/>
                    <measurement group_id="O5" value="267.3" spread="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Testosterone Undecanoate 237 mg BID</title>
          <description>Subjects will self-administer 237 mg oral TU BID for a 14 day Run-in Phase, followed by 5 consecutive days of twice daily dosing in a phase 1 clinic for serial PK sampling.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>iron deficiancy anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>white blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore Danoff, MD, PhD</name_or_title>
      <organization>Clarus Therapeutics Inc.</organization>
      <phone>847-562-4300</phone>
      <email>tdanoff@clarustherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

